Crossmark

In vivo treatment of experimental neurocysticercosis with praziquantel nanosuspensions—a metabolic approach

Crossref DOI link: https://doi.org/10.1007/s13346-018-0576-7

Published Online: 2018-08-16

Published Print: 2018-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Silva, Luciana Damacena

Lima, Nayana Ferreira

Arrua, Eva Carolina

Salomon, Claudio Javier https://orcid.org/0000-0003-1599-790X
Vinaud, Marina Clare
Funding

Funding for this research was provided by:

CNPq (471009/2013-0)

MYNCIT (2012-1078)
License Information

Text and Data Mining valid from 2018-08-16
More Information

Article History

First Online: 16 August 2018

Compliance with ethical standards

:

: All institutional and national guidelines for the care and use of laboratory animals were followed. This study was authorized by the Ethics Committee for Animal Use (CEUA/UFG) (registration number 050/13).

: The authors declare that they have no conflict of interest.